Accès ouvert
2026
article
OpenAlex
Aleksandra Konieczna, Małgorzata Pieniążek, Justyna Żubrowska, Anna Polakiewicz-Gilowska et autres
BACKGROUND: Older adults with metastatic triple-negative breast cancer (mTNBC) remain underrepresented in clinical trials. Although sacituzumab govitecan (SG) improved outcomes in the phase III ASCENT trial, real-world data in older populations remain limited. MATERIALS AND METHODS: We conducted a retrospective, multinational study …
hu, pl, cz, sk, gb
(code pays fourni par la source)
Accès ouvert
2026
article
OpenAlex
Małgorzata Pieniążek, K Swiderska, Aleksandra Konieczna, Iwona Danielewicz et autres
BACKGROUND: Programmed death-ligand 1 (PD-L1) expression assessed by the combined positive score (CPS) is required for eligibility to first-line pembrolizumab-based therapy in metastatic triple-negative breast cancer (mTNBC). However, the predictive value of CPS beyond treatment eligibility, particularly for disease control, response kinetics …
pl, hu
(code pays fourni par la source)
2026
article
OpenAlex
Miroslawa Puskulluoglu, Joanna Kiszka, Aleksandra Konieczna, Miloš Holánek et autres
e13118 Background: In KEYNOTE-355, pembrolizumab plus chemotherapy improved efficacy versus chemotherapy alone in first-line advanced triple-negative breast cancer (TNBC) with programmed death-ligand 1 (PD-L1) combined positive score (CPS)≥10 (median progression-free survival [mPFS] 9.7 vs 5.6 months [mo]; median overall survival [mOS] 23.0 …
pl, cz, sk
(code pays fourni par la source)
2026
article
OpenAlex
Marcin Kubeczko, Mirosława Püsküllüoğlu, Miloš Holánek, Dana Dvořáková et autres
e13111 Background: The treatment landscape of metastatic triple-negative breast cancer (mTNBC) is rapidly evolving. Pembrolizumab with chemotherapy has been the first-line standard; more recently, improved efficacy has been reported with sacituzumab govitecan. Therefore, biomarkers beyond PD-L1 CPS are urgently needed to better …
pl, cz, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Małgorzata Podskarbi, Aleksandra Konieczna, Miloš Holánek, K Swiderska et autres
e13125 Background: Pembrolizumab+chemotherapy (P+C) is a standard first-line treatment for PD-L1 positive metastatic triple-negative breast cancer (mTNBC). Thyroid dysfunction is a common immune-related adverse event (irAE) of PD-1 blockade and has been associated with improved outcomes in other malignancies, particularly non–small cell …
pl, cz, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Marcin Kubeczko, Miroslawa Puskulluoglu, Miloš Holánek, Malgorzata Meluch et autres
e13112 Background: Despite the addition of pembrolizumab to chemotherapy, the prognosis of patients with symptomatic metastatic triple-negative breast cancer (mTNBC) remains poor. We evaluated the indications, toxicity, and outcomes of radiotherapy (RT) added to pembrolizumab and chemotherapy in real-world mTNBC. Methods: This …
pl, cz, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Małgorzata Pieniążek, Karolina Winsko-Szczęsnowicz, Aleksandra Konieczna, Iwona Danielewicz et autres
e13108 Background: Advanced cancer is a systemic disease with inflammation recognized as one of its key hallmarks. Ratios such as Systemic Immune-Inflammation Index (SII), Systemic Inflammation Response Index (SIRI), Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR) and Lymphocyte-to-Monocyte Ratio (LMR) reflect systemic inflammatory …
pl
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Aleksandra Konieczna, Malgorzata Meluch, Miloš Holánek, Zuzana Bielčiková et autres
1124 Background: Patients aged ≥65 years constitute a substantial proportion of individuals with metastatic triple-negative breast cancer (mTNBC), but remain underrepresented in clinical trials due to comorbidities and concerns regarding treatment tolerability. While pembrolizumab combined with chemotherapy (P+C) has been established as …
pl, cz, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Aleksandra Konieczna, Miloš Holánek, M. Pieniazek, Justyna Żubrowska et autres
Abstract Background: Patients over 65 years constitute a substantial subset of those diagnosed with metastatic triple-negative breast cancer (mTNBC), yet are frequently underrepresented in clinical trials due to comorbidities, frailty, and polypharmacy. Sacituzumab govitecan (SG), approved for pretreated mTNBC, demonstrated comparable efficacy …
hu, cz, pl, sk, gb
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Anna Polakiewicz-Gilowska, Małgorzata Pieniążek, Miloš Holánek, Zuzana Bielčiková et autres
Abstract Background. Antibody-drug conjugates (ADC) such as sacituzumab govitecan (SG) have significantly improved outcomes in advanced triple-negative breast cancer (TNBC). However, many patients undergoing SG require radiotherapy (RT) for symptom control or oligoprogression. Clinical data on the safety of concurrent or sequential …
pl, gb, cz, hu, sk
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Justyna Żubrowska, Marcin Kubeczko, Małgorzata Pieniążek, Anna Polakiewicz-Gilowska et autres
Abstract Background: Patients with metastatic triple-negative breast cancer (mTNBC) and brain metastases (BM) constitute a subgroup with poor prognosis and limited treatment options. In the pivotal ASCENT trial, sacituzumab govitecan (SG) demonstrated clinical benefit in pretreated patients with mTNBC. An exploratory subgroup …
pl, gb, cz, sk, hu
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Justyna Żubrowska, Marcin Kubeczko, Małgorzata Pieniążek, Anna Polakiewicz-Gilowska et autres
Abstract Background Patients with metastatic triple-negative breast cancer (mTNBC) have limited treatment options and poor outcomes in later lines. Sacituzumab govitecan (SG) has shown benefit in this setting, including among those previously treated with programmed death-1 (PD-1) inhibitors. In the ASCENT trial, …
pl, gb, hu, cz, sk
(code pays fourni par la source)